Zydus Lifesciences Limited (NSE:ZYDUSLIFE)

Market Cap	902.49B
Revenue (ttm)	244.94B +14.0%
Net Income	49.20B +14.3%
EPS	48.89 +14.6%
Shares Out	1.01B
PE Ratio	18.34
Forward PE	20.68
Dividend	11.00 (1.23%)
Ex-Dividend Date	Jul 25, 2025

Volume	313,242
Average Volume	560,436
Open	892.50
Previous Close	893.35
Day's Range	886.45 - 899.20
52-Week Range	795.00 - 1,059.05
Beta	0.41
RSI	45.42
Earnings Date	Feb 9, 2026

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 27,917
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZYDUSLIFE

Financial Performance

In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.